Treatment of steatotic liver disease associated with metabolic dysfunction

TW202635332APending Publication Date: 2026-09-01CARMOT THERAPEUTICS INC +2
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
TW114145407
Authority / Receiving Office
TW · TW
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-10-15
Filing Date
2025-11-20
Publication Date
2026-09-01

Smart Images

  • Figure TWG2TA001074725_001
    Figure TWG2TA001074725_001
  • Figure TWG2TA001074725_002
    Figure TWG2TA001074725_002
  • Figure TWG2TA001074725_003
    Figure TWG2TA001074725_003
Patent Text Reader

Abstract

The present disclosure provides methods of treating a steatotic liver disease associated with metabolic dysfunction, such as metabolic dysfunction-associated steatohepatitis (MASH), metabolic dysfunction-associated fatty livers disease (MAFLD), or metabolic dysfunction-associated steatotic liver disease (MASLD). The treatment comprises administration of a dual GLP-1 receptor and GIP receptor agonist.
Need to check novelty before this filing date? Find Prior Art